Astrazeneca (NYSE:AZN) Given Buy Rating at Jefferies Financial Group

Posted by on Jun 26th, 2026

Astrazeneca (NYSE:AZN – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Jefferies Financial Group in a research note issued to investors on Friday,MarketScreener reports.

Several other equities analysts have also recently issued reports on AZN. Weiss Ratings cut shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 18th. Barclays reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Finally, Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $205.33.

View Our Latest Analysis on AZN

Astrazeneca Stock Performance

Shares of NYSE AZN traded up $3.08 during trading on Friday, reaching $188.76. The stock had a trading volume of 333,296 shares, compared to its average volume of 2,484,672. The stock has a market cap of $292.75 billion, a PE ratio of 28.31, a P/E/G ratio of 1.59 and a beta of 0.25. Astrazeneca has a one year low of $137.23 and a one year high of $212.71. The firm’s 50 day moving average price is $184.90 and its two-hundred day moving average price is $186.80. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN – Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. On average, research analysts forecast that Astrazeneca will post 9.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Astrazeneca

Several institutional investors and hedge funds have recently made changes to their positions in AZN. IHT Wealth Management LLC grew its stake in Astrazeneca by 0.3% during the fourth quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock worth $3,076,000 after buying an additional 54 shares during the last quarter. Visionary Wealth Advisors raised its stake in shares of Astrazeneca by 1.5% in the fourth quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock valued at $737,000 after acquiring an additional 60 shares during the last quarter. Vista Investment Management raised its stake in shares of Astrazeneca by 0.3% in the fourth quarter. Vista Investment Management now owns 21,215 shares of the company’s stock valued at $3,723,000 after acquiring an additional 60 shares during the last quarter. Kestra Investment Management LLC boosted its holdings in shares of Astrazeneca by 1.9% in the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after acquiring an additional 63 shares in the last quarter. Finally, Luken Investment Analytics LLC grew its position in Astrazeneca by 4.3% during the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock worth $274,000 after acquiring an additional 64 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Company Profile

(Get Free Report)

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

Featured Articles

Analyst Recommendations for Astrazeneca (NYSE:AZN)

Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.